• Bunge Global SA reported past second-quarter 2026 results with sales rising to US$24,041 million and net income to US$678 million, alongside higher basic and diluted earnings per share from continuing operations year on year.
• Despite six‑month sales and net income nearly doubling versus the prior year, basic and diluted earnings per share over the same period were slightly lower, highlighting the impact of a larger share base and profit mix on per‑share performance.
• With this strong quarterly earnings performance in mind, we’ll examine how the improved profitability profile influences Bunge Global’s existing investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

Bunge Global Investment Narrative Recap

To own Bunge Global, you need to believe in its role as a scaled, integrated link between global crops and demand for food, feed and fuels, supported by the Viterra combination. The latest quarter’s sharp rebound in sales and earnings strengthens the near term catalyst of improved profitability, but also underlines that margins remain sensitive to policy and trading conditions, which I see as the key risk if biofuel rules or commodity flows shift abruptly.

The most relevant recent announcement here is the completion of a large share repurchase program under the 2021 authorization, with about 19.61% of shares bought back for US$2,700 million. Set against Q2’s higher profits but softer six month EPS, this buyback history matters for the investment case, because future capital returns and any new repurchases will likely compete with ongoing Viterra integration and heavy organic investment as potential earnings catalysts.

Yet behind these stronger quarterly headlines, the real risk investors should be aware of is how much Bunge still depends on shifting biofuel policies and trade flows...

Bunge Global's narrative projects $100.1 billion revenue and $3.8 billion earnings by 2029. This requires 7.5% yearly revenue growth and about a $3.1 billion earnings increase from $686.0 million today.

Uncover how Bunge Global's forecasts yield a $142.00 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue of about US$85.2 billion and earnings of roughly US$3.1 billion by 2029, so after this strong quarter you should expect those more pessimistic views on biofuel driven margins and capacity use to be tested and perhaps updated as you compare different outlooks for the stock.

Explore 4 other fair value estimates on Bunge Global - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bunge Global research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bunge Global research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bunge Global's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.